INTRODUCTION: The objectives of this study were to evaluate quality of life (QoL) in patients presenting to the Johns Hopkins Pancreas Multidisciplinary Clinic (PMDC), and to examine associations between disease status, performance status, and QoL in order to identify patient subgroups that are most at risk for reduced QoL. PATIENTS AND METHODS: Data from 77 patients were evaluated. At initial presentation, disease and performance status were assessed, as well as QoL, which was obtained with the European Organisation for Research and Treatment of Cancer QLQ-PAN26 questionnaire. Statistical analyses examined associations between QoL, disease status, and performance status. RESULTS: Digestive symptoms (P < .003) significantly differed by pancreatic disease status (resectable, resected, locally advanced, and metastatic). Patients with a worse performance status, defined as Eastern Cooperative Oncology Group ≥ 1, were more likely to report symptomatic pancreatic pain (P = .001), digestive symptoms (P = .017), cachexia (P = .004), and ascites (P < .001) compared with patients with a performance status of 0. The majority (92%) of patients reported a significant fear of future health problems, regardless of disease status or performance status. CONCLUSION: Although several measures of QoL have been observed in all patients, certain measures appear to correlate specifically with worse disease status. Therefore, routine assessment of QoL is suggested in order to guide treatment decisions. Further investigation on optimizing the use of QoL measures and patient-reported outcomes to better tailor management is warranted.
INTRODUCTION: The objectives of this study were to evaluate quality of life (QoL) in patients presenting to the Johns Hopkins Pancreas Multidisciplinary Clinic (PMDC), and to examine associations between disease status, performance status, and QoL in order to identify patient subgroups that are most at risk for reduced QoL. PATIENTS AND METHODS: Data from 77 patients were evaluated. At initial presentation, disease and performance status were assessed, as well as QoL, which was obtained with the European Organisation for Research and Treatment of Cancer QLQ-PAN26 questionnaire. Statistical analyses examined associations between QoL, disease status, and performance status. RESULTS: Digestive symptoms (P < .003) significantly differed by pancreatic disease status (resectable, resected, locally advanced, and metastatic). Patients with a worse performance status, defined as Eastern Cooperative Oncology Group ≥ 1, were more likely to report symptomatic pancreatic pain (P = .001), digestive symptoms (P = .017), cachexia (P = .004), and ascites (P < .001) compared with patients with a performance status of 0. The majority (92%) of patients reported a significant fear of future health problems, regardless of disease status or performance status. CONCLUSION: Although several measures of QoL have been observed in all patients, certain measures appear to correlate specifically with worse disease status. Therefore, routine assessment of QoL is suggested in order to guide treatment decisions. Further investigation on optimizing the use of QoL measures and patient-reported outcomes to better tailor management is warranted.
Authors: Matthew H G Katz; Robert Wolff; Christopher H Crane; Gauri Varadhachary; Milind Javle; E Lin; Douglas B Evans; Jeffrey E Lee; Jason B Fleming; Peter W T Pisters Journal: Ann Surg Oncol Date: 2011-06-24 Impact factor: 5.344
Authors: M J Duffy; C Sturgeon; R Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann Journal: Ann Oncol Date: 2009-08-18 Impact factor: 32.976
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Pablo E Serrano; Joseph M Herman; Kent A Griffith; Mark M Zalupski; Edward J Kim; Tanios S Bekaii-Saab; Edgar Ben-Josef; Laura A Dawson; Jolie Ringash; Alice C Wei Journal: Int J Radiat Oncol Biol Phys Date: 2014-08-04 Impact factor: 7.038
Authors: Stefano Crippa; Ismael Domínguez; J Ruben Rodríguez; Oswaldo Razo; Sarah P Thayer; David P Ryan; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2008-03-04 Impact factor: 3.452
Authors: Loveena Sreedharan; Bhaskar Kumar; Anna Jewell; Paul Banim; Andreas Koulouris; Andrew R Hart Journal: Frontline Gastroenterol Date: 2018-10-09
Authors: Anne A Eaton; Mithat Gonen; Paul Karanicolas; William R Jarnagin; Michael I D'Angelica; Ronald DeMatteo; T Peter Kingham; Peter J Allen Journal: Ann Surg Oncol Date: 2016-01-19 Impact factor: 5.344
Authors: Esther N Pijnappel; Willemieke P M Dijksterhuis; Mirjam A G Sprangers; Simone Augustinus; Judith de Vos-Geelen; Ignace H J T de Hingh; Izaak Q Molenaar; Olivier R Busch; Marc G Besselink; Johanna W Wilmink; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2022-02-15 Impact factor: 3.359